Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by longterm56on Dec 06, 2018 7:35pm

221 Views

Post# 29079615

Big Picture

Although I can get quite cynical at times ... especially with SPCEO1's longterm, blatant, and continuous optimism ... I have to say that there is MUCH more upside potential than downside risk with THERF. With Trogarzo, it has cleared all the risky boxes and the only thing left is "how will it sell?" (good/better/best). With Egrifta ... solid performer with a few opportunities to really excel!

I'm embarassed to mention the total exposure I have with THERF, but ... for me ... right now ... long and strong!

-LT

Bullboard Posts

Canadians having more difficulty saving for retirement, study finds